Contacter le RP

Pour utiliser cette fonctionnalité, vous devez bénéficier d'un compte Babbler.

arrow_back

Babbler permet aux journalistes et communicants de collaborer plus simplement.

En vous connectant, vous pourrez accéder gratuitement aux espaces presse des centaines d'entreprises de vos secteurs qui sont sur Babbler, entrer en contact direct avec leurs équipes RP mais aussi y partager vos prochains sujets !

Leurs espaces presse sont sur Babbler :

Vous êtes à 1 clic de l'inscription !

Précédent

Content de vous revoir !

Communiqué

Bertrand DELUARD appointed President & Chief Executive Officer of the Ethypharm Group
timer minutes de lecture minute de lecture

Copier le lien
Ethypharm's Supervisory Board is delighted to announce the appointment of Bertrand Deluard as Group CEO.

Cliquez sur l'image pour obtenir le format original

St-Cloud, France – 31 July 2019 – Ethypharm’s Supervisory Board is delighted to announce the appointment of Bertrand DELUARD as Group President & CEO.

 

Following an announced transitional period, Bertrand DELUARD is taking over from Hugues LECAT who will become President of the Supervisory Board


Bertrand DELUARD, 58, has more than 30 years’ experience and a successful track record within the drugs and medical devices industry, having worked for the biggest groups in France (Rhône Poulenc, Aventis) and internationally (GSK, Johnson & Johnson, Cardinal Health). He has considerable leadership experience in different types of markets in Europe, the United States and in emerging countries. Bertrand is in charge of the Group’s accelerated Transformation, to make Ethypharm a European leader in the domains of CNS and Critical Care.


He stated, “The Ethypharm Group is entering an ambitious new phase of growth and expanding its portfolio of speciality products. I am proud to work alongside the management team and the Group’s 1,400 employees to implement a strategy focusing on the unmet needs of patients & healthcare professionals”.


About Ethypharm

 

Ethypharm is a European-based specialty pharmaceutical Group with global reach. It is a committed player in the domains of CNS (addictions and pain) and Critical Care. These two core therapeutic areas accounted for 64% of our turnover in 2018. The Group has 1,400 employees worldwide, mainly based in France, the United Kingdom, Germany and China and is available for patients in over 80 countries. For over 40 years, Ethypharm’s employees have been making every effort to improve patients’ lives by providing high-quality drugs to respond to unmet medical needs. Ethypharm works closely with healthcare professionals and authorities to ensure appropriate use and access to its drugs for as many as possible all around the world.

For more information about the Ethypharm Group, go to http://www.ethypharm.com and follow @ethypharm on Linkedin.


Press contact – Avril PONNELLE /presse@ethypharm.com/+ 33 (0) 1 41 12 17 20

Autres actualités de la marque

inscrit avec succès

Félicitations, vous êtes inscrit sur BABBLER !

Pour découvrir dès maintenant toutes les actualités qui vous attendent sur Babbler, consultez votre newsfeed !

Vos domaines ont été préselectionnés. Vous pouvez les compléter en cliquant ici